Dr. Michael Ephraim Wechsler, MD

Dr. Wechsler practices at National Jewish Health in Denver, Colorado, part of National Jewish Health.

Dr. Wechsler's NPI, 1528017993, was assigned on May 10, 2006. Dr. Wechsler holds Colorado license 51685.

Dr. Wechsler's primary practice is National Jewish Health, at 1400 Jackson St, Denver, CO 80206 in Denver County. The practice phone is (303) 388-4461.

Dr. Wechsler's primary practice is National Jewish Health in Denver, Colorado, part of National Jewish Health. The medical group on file is National Jewish Health. Dr. Wechsler's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Wechsler practices. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Wechsler's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Wechsler is licensed in Colorado.

CMS data shows 30 Medicare services from Dr. Wechsler across 1 procedure code in 2024, all of them office visits, for 35 Medicare patients. Medicare paid $3,248 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 35 Medicare patients who saw Dr. Wechsler in 2024. The largest group is 65 to 74, with 16 patients. 75% of them have asthma, and 66% have high cholesterol. Their average risk score is 1.43, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Wechsler's median patient age at 70, with 43% women.

In 2024, Dr. Wechsler wrote 403 Medicare Part D claims for 44 patients. 31% of them were for generic drugs. CMS names the drug for 272 of them, across 11 drugs with 11 or more claims each, at $575,316 in total drug cost. In 2023, CMS named 232 claims across 11 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 82 out of 100 for Dr. Wechsler for performance year 2024, reported as part of a group. Dr. Wechsler accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Wechsler as offering telehealth.

Dmand AI links 76 papers to Dr. Wechsler, published from 2022 to 2025. 2024 was the busiest year, with 25. The most frequent topics are Asthma, Anti-Asthmatic Agents and Biological Products. Dr. Wechsler has published most often in J Allergy Clin Immunol Pract. Dr. Wechsler's most frequent co-authors are Matthew J. Peters, Eileen Wang, MD and Flavia Cecilia Lega Hoyte, MD.

Dmand AI links Dr. Wechsler to 4 clinical trials. 1 is still active or recruiting. Conditions studied include Asthma and Respiratory Hypersensitivity. Sanofi sponsors the most, 4. Open Payments lists research payments to Dr. Wechsler that name 6 trials.

CMS Open Payments shows 2,370 general payments to Dr. Wechsler from 29 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 40% of the total. Sanofi and Genzyme US Companies paid the most, $1,028,033. It also lists 61 research payments totaling $26,651 from 2018 to 2025, naming 6 clinical trials.